Overview

Welcome to Dwaey, specifically on PRALAN 20mg Gastro-resistant tablet page.
This medicine contains an important and useful components, as it consists of Pantoprazole (as Sodium sesquihydrate.
PRALAN 20mg is available in the market in concentration 20 mg/ tablet and in the form of Gastro-resistant tablet.

ANNORA PHARMA FZ-LLC is the producer of PRALAN 20mg and it is imported from UAE, The most popular alternatives of PRALAN 20mg are listed downward .

Mode Of Action & Indication

Pantoprazole is a substituted benzimidazole, and also known as PPI due to its property to block the final step of acid secretion by inhibiting H+/K+ ATPase enzyme system in gastric parietal cell. Both basal and stimulated acid are inhibited.

Indication

• Peptic ulcer disease
• H. pylori infection
• Gastro-oesophageal reflux disease
• Zollinger-Ellison syndrome
• Oesophagitis
• Acid-related dyspepsia
• NSAID-associated ulceration
• ulcer resistant to H2 receptor antagonists
• Gastrointestinal (GI) bleeding from stress
• Prophylaxis for acid aspiration syndrome during induction of anaesthesia

Precaution

Gastric malignancy should be ruled out. Consider Zn++ supplementation during IV therapy in patients who are prone to Zn++ deficiency. Pregnancy. Monitoring Parameters Monitor Mg levels prior to initiation and periodically during prolonged use. Lactation: Not known whether pantoprazole is distributed into breast milk; not recommended

Side Effects

• 1-10% Headache (>4%)
• Abdominal pain (4%)
• Facial edema (<4%)
• Generalized edema (<2%)
• Chest pain (4%)
• Diarrhea (4%)
• Constipation (<4%)
• Pruritus (4%)
• Rash (4%)
• Flatulence (<4%)
• Hyperglycemia (1%)
• Nausea (1%)
• Vomiting (>4%)
• Photosensitivity (<2%) Frequency Not Defined Angioedema
• Atrophic gastritis
• Anterior ischemic optic neuropathy
• Hepatocellular damage leading to hepatic failure
• Interstitial nephritis
• Pancreatitis
• Pancytopenia
• Rhabdomyolysis
• Risk of anaphylaxis
• Stevens-Johnson syndrome
• Fatal toxic epidermal necrolysis
• Erythema multiforme

Contra indication

Concomitant use w/ rilpivirine, atazanavir and nelfinavir. Lactation.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.